Dacomitinib-话题@MedSci

#Dacomitinib#

8篇内容 | 949人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1752062, encodeId=7ded1e520624b, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=74, createdTime=2022-05-12, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752063, encodeId=be231e5206337, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=58, createdTime=2023-03-01, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752061, encodeId=f6431e5206128, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=57, createdTime=2022-04-29, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752060, encodeId=8bb51e520605c, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=辉瑞在欧盟和美国提交肺癌药物dacomitinib 的申请, objectType=article, longId=134397, objectId=798013439ecc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=798013439ecc, replyNumber=0, likeNumber=73, createdTime=2019-02-17, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=798013439ecc, moduleTitle=辉瑞在欧盟和美国提交肺癌药物dacomitinib 的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=798013439ecc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752058, encodeId=18271e5205845, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。, objectType=article, longId=114247, objectId=305411424ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=305411424ece, replyNumber=0, likeNumber=63, createdTime=2018-05-14, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=305411424ece, moduleTitle=Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=305411424ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752059, encodeId=48a21e5205978, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Cancer Lett：新型自噬抑制剂千金藤碱能够增强非小细胞肺癌中dacomitinib的抗癌作用。, objectType=article, longId=116331, objectId=3f4e116331a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4e116331a5, replyNumber=0, likeNumber=63, createdTime=2017-10-31, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4e116331a5, moduleTitle=Cancer Lett：新型自噬抑制剂千金藤碱能够增强非小细胞肺癌中dacomitinib的抗癌作用。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4e116331a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, objectType=article, longId=50462, objectId=d8575046299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8575046299, replyNumber=0, likeNumber=56, createdTime=2016-03-31, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8575046299, moduleTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8575046299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752056, encodeId=166f1e520560d, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, objectTitle=JCO：Dacomitinib优于厄洛替尼？, objectType=article, longId=12977, objectId=90b8129e7bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90b8129e7bd, replyNumber=0, likeNumber=75, createdTime=2013-09-15, rootId=0, userName=soongzhihua, userId=548936445000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90b8129e7bd, moduleTitle=JCO：Dacomitinib优于厄洛替尼？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90b8129e7bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Dacomitinib

2020-05-29

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2022-05-12

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2023-03-01

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2022-04-29

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

辉瑞在欧盟和美国提交肺癌药物dacomitinib 的申请

2019-02-17

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。

2018-05-14

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Cancer Lett：新型自噬抑制剂千金藤碱能够增强非小细胞肺癌中dacomitinib的抗癌作用。

2017-10-31

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价

2016-03-31

soongzhihua (审核中...)

前往app查看评论内容

#Dacomitinib#

JCO：Dacomitinib优于厄洛替尼？

2013-09-15

科室
- - 订阅+
  - 更多科室
工具
服务